TNXP Tonix Pharmaceuticals | $20.00
+10.9% | 2/28/2024 | Initiated by | Dawson James | - | Buy | $9,600.00 | Low | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 2/28/2024 |
DARE Daré Bioscience | $2.98
+1.7% | 1/30/2024 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Daré Bioscience (NASDAQ:DARE) on 1/30/2024 |
BYRN Byrna Technologies | $23.78
+5.4% | 9/27/2023 | Downgraded by | Dawson James | - | Buy -> Neutral | | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/27/2023 |
HILS Hillstream BioPharma | $1.73
+16.9% | 7/17/2023 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Hillstream BioPharma (NASDAQ:HILS) on 7/17/2023 |
BYRN Byrna Technologies | $23.78
+5.4% | 7/12/2023 | Target Lowered by | Dawson James | - | | $9.50 -> $7.25 | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 7/12/2023 |
TOON Kartoon Studios | $0.65
+7.3% | 7/11/2023 | Target Lowered by | Dawson James | - | | $12.50 -> $10.00 | Low | View details for Dawson James rating of Kartoon Studios (NASDAQ:TOON) on 7/11/2023 |
NRXP NRx Pharmaceuticals | $2.05
-1.4% | 3/17/2023 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Low | View details for Dawson James rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 3/17/2023 |
GOVX GeoVax Labs | $1.01
+2.1% | 3/3/2023 | Initiated by | Dawson James | - | Buy | $60.00 | Low | View details for Dawson James rating of GeoVax Labs (NASDAQ:GOVX) on 3/3/2023 |
HILS Hillstream BioPharma | $1.73
+16.9% | 2/22/2023 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Low | View details for Dawson James rating of Hillstream BioPharma (NASDAQ:HILS) on 2/22/2023 |
SMSI Smith Micro Software | $1.05
-0.9% | 2/28/2023 | Target Lowered by | Dawson James | - | | $66.40 -> $28.00 | Low | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 2/28/2023 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
BCDA BioCardia | $2.68
-6.0% | 11/11/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 11/11/2022 |
BYRN Byrna Technologies | $23.78
+5.4% | 9/8/2022 | Target Lowered by | Dawson James | - | | $12.00 -> $9.50 | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/8/2022 |
PRPH ProPhase Labs | $0.33
+2.4% | 7/21/2022 | Downgraded by | Dawson James | - | Neutral -> Sell | | Low | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 7/21/2022 |
DYAI Dyadic International | $1.20
-0.5% | 7/18/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 7/18/2022 |
KURA Kura Oncology | $6.47
-0.3% | 5/16/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Kura Oncology (NASDAQ:KURA) on 5/16/2022 |
BYRN Byrna Technologies | $23.78
+5.4% | 4/26/2022 | Initiated by | Dawson James | - | Buy | $12.00 | High | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 4/26/2022 |
LCTX Lineage Cell Therapeutics | $0.49
-2.6% | 3/11/2022 | Reiterated by | Dawson James | Analyst Jason Kolbert | Buy | $6.00 | N/A | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 3/11/2022 |
SMSI Smith Micro Software | $1.05
-0.9% | 3/11/2022 | Target Lowered by | Dawson James | - | Buy | $91.20 -> $66.40 | High | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 3/11/2022 |
VUZI Vuzix | $1.94
+2.1% | 12/21/2021 | Initiated by | Dawson James | - | Buy | $15.00 | Medium | View details for Dawson James rating of Vuzix (NASDAQ:VUZI) on 12/21/2021 |
PRPH ProPhase Labs | $0.33
+2.4% | 10/13/2021 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Medium | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 10/13/2021 |
SMSI Smith Micro Software | $1.05
-0.9% | 8/5/2021 | Initiated by | Dawson James | - | Buy | $88.80 | High | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 8/5/2021 |
AVXL Anavex Life Sciences | $9.36
+0.5% | 6/21/2021 | Target Raised by | Dawson James | - | Buy | $19.00 -> $35.00 | Low | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/21/2021 |
BCDA BioCardia | $2.68
-6.0% | 4/22/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Medium | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 4/22/2021 |
BCDA BioCardia | $2.68
-6.0% | 4/16/2021 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | High | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 4/16/2021 |
FBIO Fortress Biotech | $1.83
+4.6% | 2/17/2021 | Target Raised by | Dawson James | - | Buy | $240.00 -> $315.00 | Low | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 2/17/2021 |
PRPH ProPhase Labs | $0.33
+2.4% | 1/20/2021 | Initiated by | Dawson James | - | Buy | $25.00 | High | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 1/20/2021 |
LCTX Lineage Cell Therapeutics | $0.49
-2.6% | 10/12/2020 | Reiterated by | Dawson James | - | Buy | $6.00 | N/A | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 10/12/2020 |
DARE Daré Bioscience | $2.98
+1.7% | 7/12/2020 | Reiterated by | Dawson James | - | Buy | $36.00 | High | View details for Dawson James rating of Daré Bioscience (NASDAQ:DARE) on 7/12/2020 |
AVXL Anavex Life Sciences | $9.36
+0.5% | 6/8/2020 | Reiterated by | Dawson James | - | Buy | $16.00 | Medium | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/8/2020 |
CTSO Cytosorbents | $0.94
-6.9% | 3/9/2020 | Reiterated by | Dawson James | - | Buy | $15.00 -> $17.00 | High | View details for Dawson James rating of Cytosorbents (NASDAQ:CTSO) on 3/9/2020 |
DYAI Dyadic International | $1.20
-0.5% | 2/26/2020 | Reiterated by | Dawson James | Analyst Jason Kolbert | Buy | | High | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 2/26/2020 |
IMAC IMAC | $0.03
-16.1% | 1/14/2020 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of IMAC (NASDAQ:IMAC) on 1/14/2020 |
MESO Mesoblast | $12.05
+0.9% | 12/19/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $28.00 | Low | View details for Dawson James rating of Mesoblast (NASDAQ:MESO) on 12/19/2019 |
DYAI Dyadic International | $1.20
-0.5% | 10/16/2019 | Initiated by | Dawson James | - | Buy | $14.00 | Low | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 10/16/2019 |
BCDA BioCardia | $2.68
-6.0% | 9/17/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $360.00 | Low | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 9/17/2019 |
BCDA BioCardia | $2.68
-6.0% | 9/17/2019 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Medium | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 9/17/2019 |
FBIO Fortress Biotech | $1.83
+4.6% | 8/26/2019 | Initiated by | Dawson James | - | Buy | $285.00 | High | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 8/26/2019 |
ADMA ADMA Biologics | $23.52
+1.1% | 8/12/2019 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | $4.00 | High | View details for Dawson James rating of ADMA Biologics (NASDAQ:ADMA) on 8/12/2019 |
AVXL Anavex Life Sciences | $9.36
+0.5% | 7/24/2019 | Initiated by | Dawson James | Analyst J. Kolbert | Buy | $16.00 | Low | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 7/24/2019 |
KURA Kura Oncology | $6.47
-0.3% | 7/11/2019 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | High | View details for Dawson James rating of Kura Oncology (NASDAQ:KURA) on 7/11/2019 |
Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad) I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history.
And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. All the details are waiting for you now — but you need to act before the May 1st funding window clos |
INTT inTEST | $5.96
-4.2% | 12/28/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of inTEST (NYSE:INTT) on 12/28/2018 |
ORGS Orgenesis | $2.48
+12.1% | 12/20/2018 | Reiterated by | Dawson James | Analyst C. Werther | Buy | | High | View details for Dawson James rating of Orgenesis (NASDAQ:ORGS) on 12/20/2018 |
ORGS Orgenesis | $2.48
+12.1% | 12/20/2018 | Initiated by | Dawson James | - | Buy -> Buy | | Medium | View details for Dawson James rating of Orgenesis (NASDAQ:ORGS) on 12/20/2018 |
WYY WidePoint | $4.60
+7.0% | 12/3/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of WidePoint (NYSEAMERICAN:WYY) on 12/3/2018 |
WTT Wireless Telecom Group | $2.13
| 12/3/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Wireless Telecom Group (NYSEAMERICAN:WTT) on 12/3/2018 |
CNVS Cineverse | $2.93
+2.1% | 10/22/2018 | Initiated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Cineverse (NASDAQ:CNVS) on 10/22/2018 |
FRX Fennec Pharmaceuticals | C$8.55
+20.8% | 10/10/2018 | Reiterated by | Dawson James | Analyst C. Werther | Buy | | N/A | View details for Dawson James rating of Fennec Pharmaceuticals (TSE:FRX) on 10/10/2018 |
FENC Fennec Pharmaceuticals | $6.30
+3.1% | 10/11/2018 | Initiated by | Dawson James | Analyst C. Werther | Buy | | High | View details for Dawson James rating of Fennec Pharmaceuticals (NASDAQ:FENC) on 10/11/2018 |
LUNA Luna Innovations | $0.40
-2.4% | 10/2/2018 | Initiated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Luna Innovations (NASDAQ:LUNA) on 10/2/2018 |
SSKN STRATA Skin Sciences | $2.63
-2.6% | 9/4/2018 | Initiated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of STRATA Skin Sciences (NASDAQ:SSKN) on 9/4/2018 |
VERU Veru | $0.51
-2.0% | 6/25/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | Medium | View details for Dawson James rating of Veru (NASDAQ:VERU) on 6/25/2018 |
LVO LiveOne | $0.72
+0.4% | 6/4/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | Medium | View details for Dawson James rating of LiveOne (NASDAQ:LVO) on 6/4/2018 |
ALT Altimmune | $5.77
+11.6% | 5/29/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of Altimmune (NASDAQ:ALT) on 5/29/2018 |
CVM CEL-SCI | $0.25
-5.6% | 10/16/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Neutral | | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 10/16/2017 |
PULM Pulmatrix | $6.38
-2.1% | 9/27/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | Medium | View details for Dawson James rating of Pulmatrix (NASDAQ:PULM) on 9/27/2017 |
PAVM PAVmed | $0.79
-3.6% | 9/5/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | $151.50 | High | View details for Dawson James rating of PAVmed (NASDAQ:PAVM) on 9/5/2017 |
TNXP Tonix Pharmaceuticals | $20.00
+10.9% | 8/23/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | $57,600,000.00 | Medium | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 8/23/2017 |
KURA Kura Oncology | $6.47
-0.3% | 8/8/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of Kura Oncology (NASDAQ:KURA) on 8/8/2017 |
EPIX ESSA Pharma | $1.73
-2.3% | 8/3/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of ESSA Pharma (NASDAQ:EPIX) on 8/3/2017 |
OPGN OpGen | $5.15
+0.2% | 6/19/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | Low | View details for Dawson James rating of OpGen (NASDAQ:OPGN) on 6/19/2017 |
CVM CEL-SCI | $0.25
-5.6% | 3/11/2016 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/11/2016 |
ENZ Enzo Biochem | $0.33
-14.8% | 2/9/2016 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | N/A | View details for Dawson James rating of Enzo Biochem (NYSE:ENZ) on 2/9/2016 |
SLNO Soleno Therapeutics | $75.23
+0.3% | 5/6/2015 | Initiated by | Dawson James | - | Buy | $952.50 | N/A | View details for Dawson James rating of Soleno Therapeutics (NASDAQ:SLNO) on 5/6/2015 |
CVM CEL-SCI | $0.25
-5.6% | 3/2/2015 | Initiated by | Dawson James | - | Buy | $3.00 | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/2/2015 |
PULM Pulmatrix | $6.38
-2.1% | 6/25/2014 | Initiated by | Dawson James | - | Buy | $2,400.00 | N/A | View details for Dawson James rating of Pulmatrix (NASDAQ:PULM) on 6/25/2014 |
AXGN AxoGen | $17.13
+3.9% | 5/14/2014 | Initiated by | Dawson James | - | Buy | $5.00 | N/A | View details for Dawson James rating of AxoGen (NASDAQ:AXGN) on 5/14/2014 |
NEO NeoGenomics | $7.70
+6.1% | 5/14/2014 | Initiated by | Dawson James | - | Buy | $6.00 | N/A | View details for Dawson James rating of NeoGenomics (NASDAQ:NEO) on 5/14/2014 |
AGEN Agenus | $3.11
+8.7% | 3/12/2013 | Reiterated by | Dawson James | - | Buy | | N/A | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 3/12/2013 |
MD Pediatrix Medical Group | $12.94
+1.6% | 3/12/2013 | Downgraded by | Dawson James | - | Buy -> Neutral | $80.00 | N/A | View details for Dawson James rating of Pediatrix Medical Group (NYSE:MD) on 3/12/2013 |
ARWR Arrowhead Pharmaceuticals | $14.42
+2.7% | 2/26/2013 | Initiated by | Dawson James | - | Buy | $4.00 | N/A | View details for Dawson James rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 2/26/2013 |
ATOS Atossa Therapeutics | $0.86
+1.5% | 12/20/2012 | Initiated by | Dawson James | - | Outperform | $120.00 | N/A | View details for Dawson James rating of Atossa Therapeutics (NASDAQ:ATOS) on 12/20/2012 |
BMY Bristol-Myers Squibb | $50.56
+1.9% | 12/12/2012 | Reiterated by | Dawson James | - | Market Outperform | $51.00 | N/A | View details for Dawson James rating of Bristol-Myers Squibb (NYSE:BMY) on 12/12/2012 |
AMGN Amgen | $281.22
-0.9% | 12/7/2012 | Initiated by | Dawson James | - | Outperform | $91.00 | N/A | View details for Dawson James rating of Amgen (NASDAQ:AMGN) on 12/7/2012 |
GEO The GEO Group | $31.65
+0.3% | 12/4/2012 | Downgraded by | Dawson James | - | Market Perform | | N/A | View details for Dawson James rating of The GEO Group (NYSE:GEO) on 12/4/2012 |
SRPT Sarepta Therapeutics | $63.51
+1.2% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/27/2012 |
RMTI Rockwell Medical | $1.23
+13.9% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | $132.00 | N/A | View details for Dawson James rating of Rockwell Medical (NASDAQ:RMTI) on 11/27/2012 |
AGEN Agenus | $3.11
+8.7% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 11/27/2012 |
SLS SELLAS Life Sciences Group | $1.74
+7.4% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | $150.00 | N/A | View details for Dawson James rating of SELLAS Life Sciences Group (NASDAQ:SLS) on 11/27/2012 |
CYTK Cytokinetics | $37.35
-13.0% | 11/27/2012 | Downgraded by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Cytokinetics (NASDAQ:CYTK) on 11/27/2012 |
GALT Galectin Therapeutics | $1.39
+6.9% | 7/6/2012 | Target Lowered by | Dawson James | - | Buy | $3.00 | N/A | View details for Dawson James rating of Galectin Therapeutics (NASDAQ:GALT) on 7/6/2012 |
TNXP Tonix Pharmaceuticals | $20.00
+10.9% | 4/26/2012 | Initiated by | Dawson James | - | Buy | $25,600,000.00 | N/A | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 4/26/2012 |
NFLX Netflix | $1,156.49
+2.0% | 10/28/2011 | Target Lowered by | Dawson James | - | Sell | $16.50 -> $7.14 | N/A | View details for Dawson James rating of Netflix (NASDAQ:NFLX) on 10/28/2011 |
IMUC EOM Pharmaceuticals | $0.09
-7.5% | 3/22/2011 | Initiated by | Dawson James | - | Buy | $5.00 | N/A | View details for Dawson James rating of EOM Pharmaceuticals (OTCMKTS:IMUC) on 3/22/2011 |
